| Identification | Back Directory | [Name]
Steppogenin | [CAS]
56486-94-3 | [Synonyms]
Steppogenin
norartocarpanone
2',4',5,7-Tetrahydroxyflavanone
4H-1-Benzopyran-4-one, 2-(2,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (2S)- | [Molecular Formula]
C15H12O6 | [MDL Number]
MFCD20274687 | [MOL File]
56486-94-3.mol | [Molecular Weight]
288.25 |
| Chemical Properties | Back Directory | [solubility ]
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | [form ]
Powder | [color ]
White to off-white | [InChI]
InChI=1S/C15H12O6/c16-7-1-2-9(10(18)3-7)13-6-12(20)15-11(19)4-8(17)5-14(15)21-13/h1-5,13,16-19H,6H2/t13-/m0/s1 | [InChIKey]
QBLQLKNOKUHRCH-ZDUSSCGKSA-N | [SMILES]
[C@H]1(C2=CC=C(O)C=C2O)OC2=CC(O)=CC(O)=C2C(=O)C1 |
| Hazard Information | Back Directory | [Uses]
Steppogenin is a potent inhibitor of HIF-1α and DLL4, with IC50 values of 0.56 and 8.46 μM, respectively. Steppogenin can be sued for the research of angiogenic diseases, such as those involving solid tumors[1]. | [in vivo]
Steppogenin (2 mg/kg, IP, once) inhibits tumor growth and angiogenesis[1].
Steppogenin (2 mg/kg, IP, once) shows the highest distribution to the liver and spleen (25.5-fold and 9.74-fold AUC ratio, respectively) with significantly higher T1/2[1].
Pharmacokinetic Parameters of Steppogenin in male C57BL/6 J mice[1].
| Cmax (ng/mL) | Tmax (h) | T1/2 (h) | AUC8h (ng/mL?h) | AUC∞ (ng/mL?h) | AUC ratio | | Plasma | 448 ± 113 | 0.25 | 0.49 ± 0.14 | 283 ± 98.9 | 284 ± 97.8 | 1 | | Tumor | 635 ± 114 | 0.3 ± 0.1 | 1.87 ± 0.87 | 1078 ± 494 | 1252 ± 547 | 4.58 | | Liver | 4319 ± 1063 | 0.25 | 1.72 ± 0.26 | 6733 ± 1300 | 6967 ± 1200 | 25.5 | | Lung | 521 ± 181 | 0.25 | 0.36 ± 0.12 | 261 ± 96.1 | 280 ± 106 | 1.02 | | Heart | 285 ± 15.2 | 0.25 | 0.2 | 107 ± 44.3 | 176.9 | 0.65 | | Kidney | 1225 ± 463 | 0.25 | 0.33 ± 0.01 | 628 ± 234 | 624.7 ± 238 | 2.35 | | Spleen | 6110 ± 2954 | 0.25 | 0.47 ± 0.01 | 2443 ± 1155 | 2663 ± 1289 | 9.74 | | Brain | 309 ± 95.7 | 0.25 | 1.36 ± 0.46 | 191 ± 67 | 241 ± 75.4 | 0.88 |
| Animal Model: | C57BL/6 J mice (6-week-old, male, Lewis lung carcinoma (LLC) allograft tumor model)[1] | | Dosage: | 2 mg/kg | | Administration: | IP, once | | Result: | Significantly suppressed tumor growth. |
| Animal Model: | C57BL/6 J mice (6-week-old, male, Lewis lung carcinoma (LLC) allograft tumor model)[1] | | Dosage: | 2 mg/kg | | Administration: | IP, once (Pharmacokinetic Analysis) | | Result: | Showed the highest distribution to the liver and spleen (25.5-fold and 9.74-fold AUC ratio, respectively) with significantly higher T1/2. may not be accumulated even in the highly distributed tissues after the repeated administration of steppogenin. |
| [target]
Tyrosinase | [References]
[1] Cha S, et al. Steppogenin suppresses tumor growth and sprouting angiogenesis through inhibition of HIF-1α in tumors and DLL4 activity in the endothelium. Phytomedicine. 2023 Jan;108:154513. DOI:10.1016/j.phymed.2022.154513 |
|
| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Website: |
http://www.biobiopha.com |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|